Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 18;31(4):e00021-18.
doi: 10.1128/CMR.00021-18. Print 2018 Oct.

Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection

Paul K Drain  1   2   3 , Kristina L Bajema  2 , David Dowdy  4 , Keertan Dheda  5 , Kogieleum Naidoo  6   7 , Samuel G Schumacher  8 , Shuyi Ma  9   10 , Erin Meermeier  11 , David M Lewinsohn  11 , David R Sherman  9   10
Affiliations
Review

Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection

Paul K Drain et al. Clin Microbiol Rev. .

Abstract

Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a limited understanding of its clinical pathogenic spectrum of infection and disease. Historically, scientific research, diagnostic testing, and drug treatment have focused on addressing one of two disease states: latent TB infection or active TB disease. Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses. This revised understanding leads us to propose two additional clinical states: incipient and subclinical TB. The recognition of incipient and subclinical TB, which helps divide latent and active TB along the clinical disease spectrum, provides opportunities for the development of diagnostic and therapeutic interventions to prevent progression to active TB disease and transmission of TB bacilli. In this report, we review the current understanding of the pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention of both incipient and subclinical TB, two emerging clinical states of an ancient bacterium.

Keywords: Mycobacterium tuberculosis; tuberculosis.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Pathways of tuberculosis disease progression. After initial exposure, M. tuberculosis may be eliminated by the host immune response, persist as a latent infection, or progress to primary active disease. Following the establishment of latent infection, disease may persist in a latent form, naturally progress in a slow or rapid fashion to active tuberculosis, or cycle through incipient and subclinical states before developing into symptomatic disease or eventual disease resolution. Although not all possibilities for regression of disease burden are depicted, spontaneous recovery may occur in any of these clinical trajectories.
FIG 2
FIG 2
Primary and secondary disease states for the five categorical states of TB. Clinical outcomes following treatment are variable and depend on the respective pathophysiological outcomes. MTB, M. tuberculosis.
None
None
None
None
None
None
None
None
None
None
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. 2016. Global tuberculosis report. World Health Organization, Geneva, Switzerland.
    1. Houben RM, Dodd PJ. 2016. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 13:e1002152. doi:10.1371/journal.pmed.1002152. - DOI - PMC - PubMed
    1. World Health Organization. 2014. The end TB strategy. World Health Organization, Geneva, Switzerland.
    1. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. 2016. Tuberculosis. Nat Rev Dis Primers 2:16076. doi:10.1038/nrdp.2016.76. - DOI - PubMed
    1. Cadena AM, Fortune SM, Flynn JL. 2017. Heterogeneity in tuberculosis. Nat Rev Immunol 17:691–702. doi:10.1038/nri.2017.69. - DOI - PMC - PubMed

MeSH terms

Substances